Letrozole Sandoz

Letrozole, the active ingredient in Letrozole Sandoz, is an aromatase inhibitor presented as an oral tablet for oral administration. By blocking the conversion of androgens to estrogen, it lowers circulating estrogen levels and is employed in the treatment of hormone‑responsive breast cancer in post‑menopausal patients.

GNH USA supplies Letrozole Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, providing reliable access to quality‑assured medication for cancer care and supporting treatment programs across diverse regulatory environments.

Letrozole is an aromatase inhibitor used in hormone‑dependent breast cancer management.

- Early‑stage estrogen receptor‑positive breast cancer: reduces risk of recurrence after surgery. - Advanced or metastatic breast cancer: slows disease progression in post‑menopausal women. - Adjuvant therapy for hormone‑responsive breast cancer: improves disease‑free survival when combined with other agents.

Letrozole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hot flashes - Joint and muscle pain - Fatigue - Nausea - Headache - Dizziness

Serious or Rare Side Effects: - Severe bone loss or osteoporosis leading to fractures - Thromboembolic events such as deep‑vein thrombosis - Significant liver enzyme elevations or hepatitis - Severe allergic reactions including anaphylaxis - Cardiovascular events like myocardial infarction - Interstitial lung disease or pneumonitis

When prescribing Letrozole, clinicians should consider several safety measures.

- Bone health monitoring: assess bone mineral density periodically due to risk of osteoporosis. - Cardiovascular assessment: evaluate patient history for thromboembolic or cardiac disease. - Liver function testing: monitor hepatic enzymes before and during therapy. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Letrozole can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Estrogen replacement therapy: antagonizes Letrozole’s estrogen‑lowering effect. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may markedly reduce Letrozole plasma levels. - Tamoxifen: concurrent use may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - CYP2C9 substrates (e.g., warfarin): Letrozole may alter anticoagulant control. - Statins metabolized by CYP3A4: monitor for increased statin exposure. - Other hormonal agents (e.g., GnRH analogues): assess combined endocrine effects.